Regeneron (REGN), Sanofi (SNY) Announce Presentation of Strong Sarilumab Monotherapy Phase 3 Data vs. Humira
Tweet Send to a Friend
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Sanofi (NYSE: SNY) will present results of SARIL-RA-MONARCH, a Phase 3 study, which demonstrated ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
